You are here

  • Home
  • Online First
  • Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

Article metrics

Article menu

other Versions

Download PDFPDF

Clinical trial
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

 

Online download statistics by month:

Online download statistics by month: November 2021 to June 2023

AbstractFullPdf
Nov 2021455430230
Dec 2021842820318
Jan 202213651386450
Feb 2022882881249
Mar 2022800801225
Apr 2022479493132
May 2022570576161
Jun 2022386388118
Jul 2022346341122
Aug 2022382361106
Sep 2022348330120
Oct 202230629779
Nov 2022439423128
Dec 202224823788
Jan 2023301290103
Feb 2023369362122
Mar 2023488483192
Apr 2023414405165
May 2023409402147
Jun 202338384
Total986797443259